Comment on CMS-2026-1255-0001

Summary: AstraZeneca, a global biopharmaceutical company, supports the CMS proposed rule to improve interoperability and transparency in prior authorization processes for prescription drugs. They advocate for specific enhancements, including standardized electronic workflows, more frequent data updates, and safeguards to prevent site-of-care steering and administrative delays, particularly for rare disease patients.